Clofarabine as a potential stimulant of alloreactivity
Authors:
- 13 December 2010
- journal article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 46 (10) , 1393-1394
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Graft-versus-leukemia effects of transplantation and donor lymphocytesBlood, 2008
- High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin LymphomaTransplantation and Cellular Therapy, 2008
- Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI aloneBlood, 2007
- Factors for graft‐versus‐host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell doseBritish Journal of Haematology, 2007
- Phase II Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2006
- Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic MelanomaJournal of Clinical Oncology, 2005
- Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaBlood, 2003
- Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusionsBone Marrow Transplantation, 2003
- Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated miceBlood, 2001